

EFFECTIVE DATE: 07|01|2012

POLICY LAST UPDATED: 03|17|2015

OVERVIEW

Microwave ablation (MWA) is a technique to destroy tumors and soft tissue by using microwave energy to create thermal coagulation and localized tissue necrosis. MWA is used to treat tumors considered to be inoperable or not amenable to resection or to treat patients ineligible for surgery due to age, presence of comorbidities, or poor general health. MWA may be performed as an open procedure, laparoscopically, percutaneously, or thoracoscopically under image guidance (e.g., ultrasound, computed tomography [CT] or magnetic resonance imaging [MRI]) with sedation, or local or general anesthesia. This technique may also be referred to as microwave coagulation therapy.

MEDICAL CRITERIA

Not applicable.

PRIOR AUTHORIZATION

Not applicable.

POLICY STATEMENT

BlueCHiP for Medicare and Commercial

Microwave ablation of primary and metastatic tumors is considered not medically necessary due to the lack of published medical literature that demonstrates the efficacy of this procedure.

COVERAGE

Benefits may vary between groups/contracts. Please refer to the appropriate Evidence of Coverage or Subscriber Agreement for the applicable “not medically necessary” coverage/benefits.

BACKGROUND

Microwave ablation (MWA) is a technique in which the use of microwave energy induces an ultra-high speed, 915 MHz or 2450MHz (2.45GHz), alternating electric field that causes water molecule rotation and the creation of heat. This results in thermal coagulation and localized tissue necrosis. In MWA, a single microwave antenna or multiple antennas connected to a generator are inserted directly into the tumor or tissue to be ablated; energy from the antennas generates friction and heat. The local heat coagulates the tissue adjacent to the probe, resulting in a small, approximately 2-3 cm elliptical area (5 x 3 cm) of tissue ablation. In tumors > 2 cm in diameter, 2-3 antennas may be used simultaneously to increase the targeted area of MWA and shorten operative time. Multiple antennas may also be used simultaneously to ablate multiple tumors. Tissue ablation occurs quickly, within one minute after a pulse of energy, and multiple pulses may be delivered within a treatment session depending on the size of the tumor. The cells killed by MWA are typically not removed but are gradually replaced by fibrosis and scar tissue. If there is local recurrence, it occurs at the edges. Treatment may be repeated as needed. MWA may be used to: 1) control local tumor growth and prevent recurrence; 2) palliate symptoms; and 3) extend survival duration.

Complications from MWA are usually considered mild and may include pain and fever. Other potential complications associated with MWA include those caused by heat damage to normal tissue adjacent to the tumor (e.g., intestinal damage during MWA of the kidney or liver), structural damage along the probe track (e.g., pneumothorax as a consequence of procedures on the lung), liver enzyme elevation, liver abscess, ascites, pleural effusion, diaphragm injury, or secondary tumors if cells seed during probe removal. MWA

should be avoided in pregnant patients since potential risks to the patient and/or fetus have not been established and in patients with implanted electronic devices such as implantable pacemakers that may be adversely affected by microwave power output.

Based on review of the published data (which consists largely of small case series and limited randomized trials) and clinical input, there is insufficient evidence to permit conclusions concerning the comparative effectiveness of MWA to other ablative techniques on health outcomes. Therefore, MWA of hepatocellular carcinoma, liver metastases from primary cancers from other sites, renal cell carcinoma, other renal tumors and all other tumors is considered not medically necessary.

CODING

BlueCHiP for Medicare and Commercial

There are no CPT codes specific to microwave tumor ablation. Report the unlisted CPT code for the anatomic area.

RELATED POLICIES

None

PUBLISHED

Provider Update, May 2015
Provider Update, June 2014
Provider Update, Nov 2013
Provider Update, May 2012

REFERENCES:

1. Zhao Z, Wu F. Minimally-invasive thermal ablation of early-stage breast cancer: a systemic review. *Eur J Surg Oncol* 2010; 36 (12); 1149-55.
2. Zhou W, Zha X, Liu X et al. US-guided percutaneous microwave coagulation of small breast cancers: a clinical study. *Radiology* 2012; 263 (2); 364-73
3. Shibata T, Iimuro Y, Yamamoto Y et al. Small hepatocellular carcinoma; comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. *Radiology* 2002, 223(2) 331-7
4. Tanial N, Yoshida H, Mamada Y et al. Is intraoperative adjuvant therapy effective for satellite lesions in patients undergoing resection surgery for advanced hepatocellular carcinoma? *Hepatogastroenterology* 2006; 53(68) 258-61
5. Ong St, Gravante G, Metcalfe MS et al. Efficacy and safety of microwave ablation for primary and secondary liver malignancies: a systematic review, *Eur J Gastroenterol Hepatol* 2009; 21 (6) 599-605
6. Bertot LC, Sato M, Tateishi R et al. Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors; a systematic review. *Eur Radiol* 2011; 21(12) 2584-96
7. Lu MD, Xu HX, Xie XY et al. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. *J Gastroenterol* 2005; 40(11); 1054-60
8. Liang P, Wang Y, Yu X et al. Malignant liver tumors; treatment with percutaneous microwave ablation- complications among cohort of 1136 patients. *Radiology* 2009, 251 (3) 933-40.
9. Simo KA, Sereika SE, Newton KN et al. Laparoscopic-assisted microwave ablation for hepatocellular carcinoma: Safety and efficacy in comparison with radiofrequency ablation, *J Surg Oncol* 2011; 104 (7); 822-9
10. Ding J, Jing X, Liu J et al. Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma. *Eur J Radiol* 2013, 82(9): 1379-84.
11. Bala MM, Riemsma RP, Wolff R, et al. Microwave coagulation for liver metastases. *Cochrane Database Syst Rev.* 2013; 10:CD010163. PMID 24122576

12. Loveman E, Jones J, Clegg AJ, et al. The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation. *Health Technol Assess.* Jan 2014;18(7):vii-viii, 1-283. PMID 24484609
13. Katsanos K, Mailli L, Krokidis M, et al. Systematic review and meta-analysis of thermal ablation versus surgical nephrectomy for small renal tumours. *Cardiovasc Intervent Radiol.* Apr 2014;37(2):427-437. PMID 24482030
14. Martin J, Athreya S. Meta-analysis of cryoablation versus microwave ablation for small renal masses: is there a difference in outcome? *Diagn Interv Radiol.* Nov-Dec 2013;19(6):501-507. PMID 24084196

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

